Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard Post History

by wildbird1


V.TLT

RE:Feature article about Theralase on biotuesdays.com website

Eoganacht...Great  Article. I like the part were TLT said. "...

January 8, 2023

V.TLT

RE:RE:Has to be over 60%CR...

enriquesuave wrote: After that press release , they no longer used the 67...

December 30, 2022

V.TLT

Vaccine & therapeutic...

Before we go on the holidays break, here is a little remender for the...

December 23, 2022

V.TLT

Has to be over 60%CR...

I am one of the very few people on this board that come up with a CR% over 60...

December 21, 2022

V.TLT

RE:RE:RE:RE:RE:RE:NSCLC and GBM indications

Good post Eoganacht... Here is a quote that you can find in almost every...

December 19, 2022

V.TLT

RE:RE:RE:RE:RE:RE:RE:RE:RE:Is FDA submission material enough for an NR?

StevenBirch, here is a quote from the FDA site , as a complement to your post...

December 16, 2022

V.TLT

RE:Optimized group efficacy % @90-days: CR=65%, PR=10%, TR=75%

ScienceFirst, after reading your post and Eoganacht post, I decided to give...

December 12, 2022

V.TLT

BTD...Vaccine... Competition.

BTD timeline. In the last PressRelease TLT said " Completion of the 450...

December 4, 2022

V.TLT

Progressing in the right direction.

TLT is progressing in the right direction and nobody can contredic that fact....

December 1, 2022

V.TLT

RE:RE:N-803 had been granted Breakthrough designation. We will too

ScienceFirst great catch...(the best catch I have seen lately). If we sum-up...

November 27, 2022

V.TLT

RE:RE:TLD1433 vs Keytruda

Good points Eoganacht & CancerSlayer... In the link provided in your...

November 22, 2022

V.TLT

RE:450-days data to secure the Breakthrough designation

ScienceFirst, it is very interesting when you compare what the FDA is asking...

November 20, 2022

V.TLT

RE:Crutial 450 day data.

greaterfoolfred said, Wildbird you can not use the 4 undertreated patients...

November 14, 2022

V.TLT

Crutial 450 day data.

The 18 optimized patients 450 day data are crutial for the BTD application in...

November 13, 2022

V.TLT

RE:RE:RE:RE:Another look at the data

The optimized patients effects... I would not worries to much about the 12...

November 6, 2022

V.TLT

Three trials simultaneously...

Nobody like dilution,but sometime you have to look at the bigger picture...

October 10, 2022

V.TLT

RE:63% still have their bladder at 270 days...

For those who ask, what would the TR% look like if we were to replace the 12...

September 21, 2022

V.TLT

63% still have their bladder at 270 days...

Let's try to understand why TLT is including a TR(CR+PR) line in their...

September 18, 2022

V.TLT

191% increase in CR%

Not easy for new investors to make sense of what is coming in the Phase11...

September 11, 2022

V.TLT

RE:RE:RE:RE:how can an NR become not an NR?

Sorry the link doesn't work. Go on TLT website... in the menu... click...

September 6, 2022